At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 11, 2026 at 08:00 ET
Theriva Biologics announced publication of Phase 1 trial results for VCN-01 in immunotherapy-refractory HNSCC in Clinical Cancer Research. The data showed median overall survival of up to 17.3 months in the high-dose sequential arm, with translational evidence of immune resensitization.
- Phase 1 trial results published in Clinical Cancer Research for VCN-01 + durvalumab in immunotherapy-refractory metastatic HNSCC
- Median overall survival: 10.3 months (Arm I LD), 15.5 months (Arm II LD), 17.3 months (Arm II HD)
- Median progression-free survival: 1.6 months (Arm I LD), 3.7 months (Arm II LD), 2.1 months (Arm II HD)
- Biomarker data showed increased PD-L1+ T-cells, CD8 upregulation, and reduced Treg markers consistent with immune reactivation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access